denkapparat Operations GmbH Makes New Investment in IQVIA Holdings Inc. (NYSE:IQV)

denkapparat Operations GmbH acquired a new stake in IQVIA Holdings Inc. (NYSE:IQV) in the 4th quarter, Holdings Channel.com reports. The institutional investor acquired 1,092 shares of the medical research company’s stock, valued at approximately $215,000.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Synergy Asset Management LLC acquired a new position in shares of IQVIA during the 4th quarter worth approximately $33,000. Lee Danner & Bass Inc. bought a new position in shares of IQVIA in the fourth quarter valued at $44,000. Zions Bancorporation N.A. increased its holdings in IQVIA by 55.2% during the fourth quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company’s stock worth $47,000 after buying an additional 85 shares during the last quarter. Versant Capital Management Inc lifted its stake in IQVIA by 46.0% in the fourth quarter. Versant Capital Management Inc now owns 295 shares of the medical research company’s stock valued at $58,000 after acquiring an additional 93 shares during the last quarter. Finally, SBI Securities Co. Ltd. bought a new position in shares of IQVIA in the 4th quarter valued at about $60,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Price Performance

Shares of NYSE:IQV opened at $177.27 on Friday. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. The stock has a market capitalization of $31.25 billion, a PE ratio of 23.64, a PEG ratio of 1.99 and a beta of 1.50. The firm has a 50 day moving average of $193.15 and a 200-day moving average of $206.47. IQVIA Holdings Inc. has a 12 month low of $176.03 and a 12 month high of $253.84.

IQVIA (NYSE:IQV) last released its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. On average, equities research analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

IQV has been the subject of several recent analyst reports. Stifel Nicolaus cut their target price on shares of IQVIA from $273.00 to $261.00 and set a “buy” rating for the company in a research note on Friday, February 7th. JPMorgan Chase & Co. reduced their target price on IQVIA from $240.00 to $232.00 and set an “overweight” rating for the company in a research note on Tuesday, February 18th. William Blair reaffirmed an “outperform” rating on shares of IQVIA in a research report on Wednesday, December 11th. Truist Financial reissued a “buy” rating and issued a $263.00 price objective (up from $261.00) on shares of IQVIA in a research report on Monday, February 10th. Finally, StockNews.com lowered shares of IQVIA from a “buy” rating to a “hold” rating in a research note on Wednesday, March 12th. Five equities research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, IQVIA presently has a consensus rating of “Moderate Buy” and a consensus price target of $249.05.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.